Regenerative Stem Cell Therapy for Stroke in Europe 1 ( )
Status:
Unknown status
Trial end date:
2020-09-01
Target enrollment:
Participant gender:
Summary
Stroke is the second leading cause of death in the world population. When not fatal, stroke
often results in disability, and secondary health problems affecting not only patients but
also their families. Building on emerging preclinical and pilot clinical evidences, RESSTORE
will focus on the clinical assessment of regenerative cell therapy to improve stroke recovery
and patients quality of life.
Phase:
Phase 1
Details
Lead Sponsor:
University Hospital, Grenoble
Collaborators:
Andaluz Health Service Assistance Publique - Hôpitaux de Paris Association Groupe ESSEC Association groupe ESSEC, France Centre Hospitalier Universitaire de Besancon CH Sainte-Anne, Paris, France CHU Besancon, France CHU Bordeaux, France CHU Cote de Nacre, Caen, France CHU Toulouse, France Etablissement Français du Sang European Commission H2020 program Fakultni Nemocnice U Sv. Anny v Brne, Brno, Czech Republic Finovatis FINOVATIS, France Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau Fundación Instituto de Estudios de Ciencias de la Salud de Castilla y León Histocell SL, Spain Horizon 2020 - European Commission Hospices Civils de Lyon Hospital Vall d'Hebron Institut d'Investigació Biomèdica de Girona Dr. Josep Trueta Institut National de la Santé Et de la Recherche Médicale, France Medfiles CRO, Finland NOVADISCOVERY SAS, France Pirkanmaa Hospital District, Tampere, Finland Servicio de Salud de Castilla La Mancha, Albacete, Spain Servicio Madrileño de Salud, Madrid, Spain Servizo Galego de Saude, Santiago de Compostela, Spain St. Anne's University Hospital Brno, Czech Republic Tampere University University Grenoble Alps University Hospital, Bordeaux University Hospital, Caen University Hospital, Toulouse University of Eastern Finland University of Glasgow University of Tampere